share_log

HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50

HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50

HC Wainwright & Co.维持对Biora Therapeutics的买入,将目标价下调至50美元
Benzinga ·  2023/10/02 07:01

HC Wainwright & Co. analyst Joseph Pantginis maintains Biora Therapeutics (NASDAQ:BIOR) with a Buy and lowers the price target from $65 to $50.

HC Wainwright & Co. 分析师约瑟夫·潘吉尼斯将Biora Therapeutics(纳斯达克股票代码:BIOR)维持买入,并将目标股价从65美元下调至50美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发